TocilizuMab manufacturers
- Tocilizumab
-
-
2026-09-18
- CAS:375823-41-9
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100G
- TocilizuMab
-
- $10.00
-
2026-03-20
- CAS:375823-41-9
- Min. Order: 100KG
- Purity: 99%
- Supply Ability: 100 mt
- TocilizuMab
-
-
2025-08-22
- CAS:375823-41-9
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50kg
|
| | TocilizuMab Basic information |
| Product Name: | TocilizuMab | | Synonyms: | TocilizuMab;Actemra;Actemra 200;anti-IL-6R Tocilizumab;Atlizumab;R 1569;RoActemra;Tocilizumab,Atlizumab | | CAS: | 375823-41-9 | | MF: | C14H12O3 | | MW: | 0 | | EINECS: | 248-451-4 | | Product Categories: | API | | Mol File: | Mol File | ![TocilizuMab Structure]() |
| | TocilizuMab Chemical Properties |
| storage temp. | Store at -80°C | | solubility | Soluble in DMSO | | form | Liquid | | color | Colorless to light yellow |
| | TocilizuMab Usage And Synthesis |
| History | TocilizuMab (trade name: Actemra) is an antirheumatoid arthritis drug developed by Genentech, Inc. It was first approved by the FDA on January 8, 2010, for the treatment of moderate to severe active rheumatoid arthritis. On June 24, 2021, Actemra received Emergency Use Authorization from the FDA for the treatment of hospitalized adults and children with COVID-19, but not for outpatients with COVID-19. At this time, it had not yet received formal approval. By December 21, 2022, the FDA approved Actemra for the treatment of hospitalized adults with COVID-19. | | Uses | Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4]. | | Clinical Use | Interleukin inhibitor:
Treatment of rheumatoid arthritis in combination with methotrexate | | in vivo | Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3]. | Animal Model: | A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2] | | Dosage: | 1.0 mg/100 μL | | Administration: | Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks | | Result: | Led the volume of each metastatic focus significantly smaller. |
| Animal Model: | SCID mice with SAS cells[3] | | Dosage: | 100 μg/mL | | Administration: | Intraperitoneal injection;100 μg/mL; every 48 hours; 20days | | Result: | Suppressed the growth of advanced tumors. |
| | Drug interactions | Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant administration | | IC 50 | IL-6 | | Metabolism | Tocilizumab undergoes biphasic elimination from the circulation. The total clearance of tocilizumab is concentration-dependent and is the sum of the linear and non-linear clearance. The concentration-dependent non-linear clearance plays a major role at low tocilizumab concentrations. Once the non-linear clearance pathway is saturated, at higher tocilizumab concentrations, clearance is mainly determined by the linear clearance. | | References | [1] Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70. DOI:10.1074/jbc.M111.295758
[2] Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526. DOI:10.3390/ijms14010515
[3] Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34. DOI:10.1158/1078-0432.CCR-09-0287
[4] Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954. DOI:10.1016/j.ijantimicag.2020.105954 |
| | TocilizuMab Preparation Products And Raw materials |
|